Effects of urinary trypsin inhibitor in @entity1 at risk for XXXX with a bulging fetal membrane.

@entity1 @entity3257 @entity3152 @entity5870
OBJECTIVE: To investigate the effect of urinary trypsin inhibitor ( @entity3257 ) in @entity1 at risk for @entity3152 with bulging membrane. METHODS: @entity1 who had developed a bulging membrane from 22 to 27 weeks and 6 days of gestation were studied. These cases were divided into two types based on the severity: those with a moderately developed bulging membrane like a 'dome' (dome type), and those with a membrane prolapsed into the vagina, resulting in an 'hourglass' shape (hourglass type). We compared the outcomes of treatment with or without @entity3257 ( @entity3257 group versus @entity3257 ) in each type. Gestational age at delivery, birth weight, prolongation time from admission to delivery, and neonatal mortality rate were examined in each group. RESULTS: A total of 43 @entity1 with a bulging membrane were analyzed. In 21 @entity1 with the dome type, gestational age at delivery (the @entity3257 group versus the @entity3257 ; 30.4 +/- 5.0 versus 26.4 +/- 1.9 weeks, p < 0.05), birth weight (1,436.8 +/- 708.3 versus 882.8 +/- 261.6 g, p < 0.05) and neonatal mortality rate (0/13 versus 3/8, p < 0.05) were all significantly improved by the use of @entity3257 . On the other hand, in 22 @entity1 with the hourglass type, there was no significant difference between the @entity3257 group and the @entity3257 . The overall prevalence of histological @entity5870 was 60%. CONCLUSION: These results suggest that @entity3257 therapy is very effective in @entity1 at risk for @entity3152 with a moderately developed bulging membrane during the second trimester.
